Valeant Boosts Bid For Allergan

May 29 2014 | 12:19pm ET

Valeant Pharmaceuticals International has increased its offer for Allergan Inc. by 7%, offering more cash and additional payments in a deal backed by Pershing Square Capital Management.

Valeant increased its offer to nearly $50 billion. The Canadian company also increased the amount of cash in the deal by $10 per Allergan share, with the rest payable in Valeant shares.

The higher offer appeared to disappoint investors, which sent shares of both companies down. Allergan, which rejected Valeant’s earlier approach, said it would consider the new offer, which adds contingent value rights worth as much as $25 per share, based on the success of Allergan’s experimental new blindness drug, Darpin.

Valeant’s efforts are supported by Pershing Square, which acquired a 9.7% stake in Allergan with Valeant’s help. The two are now pursuing a non-binding shareholder referendum in favor of the pact.

“Allergan shareholders want this deal to occur, but they want a higher price and the optionality on Darpin,” Valeant CEO Michael Pearson said. “We think the offer we made this morning address both of those concerns.”

Pershing Square chief William Ackman attended Valeant’s announcement but did not comment.


In Depth

An Interview With Harvest Volatility Management's Rick Selvala

Mar 23 2017 | 5:39pm ET

Several years of extremely low interest rates have pushed some investors into equities...

Lifestyle

'Tis the Season: Wall Street Holiday Parties Back In Fashion

Dec 22 2016 | 9:23pm ET

Spending on Wall Street holiday parties has largely returned to pre-2008 levels...

Guest Contributor

SEI: Private Debt Coming Into Its Own

Mar 8 2017 | 9:24pm ET

The explosive growth of private debt over the past few years has caused the lines...

 

From the current issue of